Effect of metabolic dysfunction on the risk of liver-related events in patients cured of hepatitis C virus DOI Open Access
Wei‐Fan Hsu, Hsueh‐Chou Lai, Sheng‐Hung Chen

и другие.

American Journal of Cancer Research, Год журнала: 2024, Номер 14(4), С. 1914 - 1925

Опубликована: Янв. 1, 2024

The impact of metabolic dysfunction or dysfunction-associated fatty liver disease (MAFLD) on liver-related events (LREs) in patients with chronic hepatitis C (CHC) who had achieved a sustained virologic response (SVR) to direct-acting antiviral agents (DAAs) is unknown.A total 924 cured CHC and documented body mass index (BMI) were included the analysis, data period was from September 2012 April 2022.Hepatic steatosis identified either through ultrasonography blood biomarkers.Metabolic defined as presence overweight obesity (BMI ≥ 23 kg/m 2 ), type diabetes mellitus (DM), dysregulation.Patients may have more than one dysfunction.Variables at 12 24 weeks after DAA therapy (PW12) used identify predictors LREs.The median age 58 (49-65) years.Of participants, 418 (45.2%) male.The BMI 24.01 (21.78-26.73)kg/m , 174 (18.8%) DM.A multivariable Cox regression analysis revealed that age, male, albumin, bilirubin, alphafetoprotein (AFP), (hazard ratio: 1.709, 95% confidence interval: 1.128-2.591,P = .011),and FIB-4 > 3.25 independent LREs.Type DM dysregulation exhibited larger time-dependent area under receiver operating characteristic curve for LREs did obesity.Moreover, be an predictor hepatocellular carcinoma.Metabolic increased risk HCC SVR therapy.

Язык: Английский

The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver disease DOI Creative Commons
Mohammed Eslam, Jian‐Gao Fan, Ming‐Lung Yu

и другие.

Hepatology International, Год журнала: 2025, Номер unknown

Опубликована: Фев. 27, 2025

Язык: Английский

Процитировано

5
Chronic Hepatitis C Related Steatotic Liver Disease Is More Than “Miscellaneous Steatotic Liver Disease” DOI
Chung‐Feng Huang,

Ming-Lun Yeh,

Chia‐Yen Dai

и другие.

Clinical Gastroenterology and Hepatology, Год журнала: 2024, Номер 22(10), С. 2137 - 2139.e2

Опубликована: Май 9, 2024

Язык: Английский

Процитировано

4
Performance of noninvasive seromarkers in predicting liver fibrosis among MAFLD patients with or without viral hepatitis DOI Creative Commons
Chung‐Feng Huang, Po‐Cheng Liang, Chih‐Wen Wang

и другие.

The Kaohsiung Journal of Medical Sciences, Год журнала: 2024, Номер 40(4), С. 374 - 383

Опубликована: Янв. 17, 2024

Abstract The accuracy of noninvasive seromarkers in predicting liver fibrosis metabolic dysfunction‐associated fatty disease (MAFLD) patients with or without viral hepatitis is elusive. AST to platelet ratio index (APRI), fibrosis‐4 (FIB‐4), and NAFLD score (NFS) were assessed 871 MAFLD who received elastography a hepatitis‐endemic area. area under the receiver operating characteristic (AUROC) curve increased substantially increasing fibrotic stage across three biomarkers. APRI (AUROC range 0.73–0.80) FIB‐4 0.66–0.82) performed better than NFS 0.63–0.75). When divided into non‐viral groups, AUROC (range 0.76–0.80) 0.68–0.78) 0.62–70) existed only MALFD but not MAFLD. Regarding NFS, was higher 0.69–0.86) outperformed at all stages. advancement for exerted diagnostic different best 91.1% using cutoff value −9.98 cirrhosis patients. as whole. suboptimal performance Caution should be taken when assessing hepatitis.

Язык: Английский

Процитировано

2
Effect of metabolic dysfunction on the risk of liver-related events in patients cured of hepatitis C virus DOI Open Access
Wei‐Fan Hsu, Hsueh‐Chou Lai, Sheng‐Hung Chen

и другие.

American Journal of Cancer Research, Год журнала: 2024, Номер 14(4), С. 1914 - 1925

Опубликована: Янв. 1, 2024

The impact of metabolic dysfunction or dysfunction-associated fatty liver disease (MAFLD) on liver-related events (LREs) in patients with chronic hepatitis C (CHC) who had achieved a sustained virologic response (SVR) to direct-acting antiviral agents (DAAs) is unknown.A total 924 cured CHC and documented body mass index (BMI) were included the analysis, data period was from September 2012 April 2022.Hepatic steatosis identified either through ultrasonography blood biomarkers.Metabolic defined as presence overweight obesity (BMI ≥ 23 kg/m 2 ), type diabetes mellitus (DM), dysregulation.Patients may have more than one dysfunction.Variables at 12 24 weeks after DAA therapy (PW12) used identify predictors LREs.The median age 58 (49-65) years.Of participants, 418 (45.2%) male.The BMI 24.01 (21.78-26.73)kg/m , 174 (18.8%) DM.A multivariable Cox regression analysis revealed that age, male, albumin, bilirubin, alphafetoprotein (AFP), (hazard ratio: 1.709, 95% confidence interval: 1.128-2.591,P = .011),and FIB-4 > 3.25 independent LREs.Type DM dysregulation exhibited larger time-dependent area under receiver operating characteristic curve for LREs did obesity.Moreover, be an predictor hepatocellular carcinoma.Metabolic increased risk HCC SVR therapy.

Язык: Английский

Процитировано

1